Pharmascience Inc. v. Janssen Inc., 2024 FC 440 (Abiraterone*)
Justice Southcott - 2024-03-19
Read full decision. Automatically generated summary:
This Order and Reasons address an appeal by the Plaintiff from the oral decision of Associate Judge Horne, the Case Management Judge in this matter ... compelling the Plaintiff to produce its financial statements from 2019 to the present, further to a question that was refused during discovery. ... As explained in greater detail below, the Plaintiff’s motion and appeal will be dismissed, as the Plaintiff has not demonstrated any reviewable error on the part of the Case Management Judge in ordering the production of the financial statements. Overall, I interpret the transcript as demonstrating that the Case Management Judge took Carvedilol into account as a precedent that supported ordering production but also considered the relevance of the financial statements to the particular defence issues Janssen raised.
Decision relates to:
- T-732-22 - PHARMASCIENCE INC. v. Janssen Inc. et Al.